{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:54:55Z","timestamp":1774072495273,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"DOI":"10.1093\/jjco\/hyw127","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T01:09:08Z","timestamp":1473383348000},"page":"1088-1094","source":"Crossref","is-referenced-by-count":7,"title":["Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study"],"prefix":"10.1093","volume":"46","author":[{"given":"Norikazu","family":"Masuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reigetsu","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutsuna","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,12,8]]},"reference":[{"key":"key\n\t\t\t\t2018110606154213400_hyw127C1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jjco\/hyu003","article-title":"Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project","volume":"44","author":"Matsuda","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12282-012-0420-8","article-title":"An overview of the Japan Breast Cancer Research Group (JBCRG) activities","volume":"20","author":"Ohno","year":"2013","journal-title":"Breast Cancer"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/jjco\/hyt038","article-title":"An updated report of the trends in cancer incidence and mortality in Japan","volume":"43","author":"Katanoda","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C4","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/746749","article-title":"Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor A","author":"Srabovic","year":"2013","journal-title":"Int J Breast Cancer"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C5","first-page":"14","article-title":"Angiogenesis in cancer: anti-VEGF escape mechanisms","volume":"1","author":"Prager","year":"2012","journal-title":"Transl Lung Cancer Res"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2217\/fon.10.75","article-title":"Ramucirumab (IMC-1121B): a novel attack on angiogenesis","volume":"6","author":"Spratlin","year":"2010","journal-title":"Future Oncol"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.13.68","article-title":"Ramucirumab: a novel antiangiogenic agent","volume":"9","author":"Wadhwa","year":"2013","journal-title":"Future Oncol"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11912-010-0149-5","article-title":"Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2","volume":"13","author":"Spratlin","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C9","first-page":"1997","article-title":"Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug","volume":"21","author":"Taguchi","year":"1994","journal-title":"Gan To Kagaku Ryoho"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/bjc.1996.37","article-title":"A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer","volume":"73","author":"Adachi","year":"1996","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jjco\/hyr081","article-title":"Docetaxel followed by fluorouracil\/epirubicin\/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer","volume":"41","author":"Iwata","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.2001.19.2.336","article-title":"Efficacy of docetaxel 60 mg\/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance","volume":"19","author":"Ando","year":"2001","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1470-2045(15)00411-8","article-title":"Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial","volume":"17","author":"Takashima","year":"2016","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C16","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2014.57.1513","article-title":"Primary results of ROSE\/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer","volume":"33","author":"Mackey","year":"2015","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C18","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s40265-013-0154-8","article-title":"Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use","volume":"73","author":"Aprile","year":"2013","journal-title":"Drugs"},{"key":"key\n\t\t\t\t2018110606154213400_hyw127C19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/46\/12\/1088\/26367957\/hyw127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T08:42:52Z","timestamp":1568364172000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/46\/12\/1088\/2528027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,8]]},"published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyw127","relation":{},"ISSN":["0368-2811","1465-3621"],"issn-type":[{"value":"0368-2811","type":"print"},{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,12,1]]},"published":{"date-parts":[[2016,12,1]]}}}